Your Genes May Predict How Much Weight You'll Lose on GLP-1s (New Study)
A massive 23andMe study published in Nature found genetic variants that predict GLP-1 weight loss (6-20%) and nausea risk (5-78%). Here's what it means for choosing your medication.
A new study using 23andMe genetic data suggests that a handful of common gene variants may predict how much weight a patient loses on semaglutide and tirzepatide. The effect size is real but modest — far from a precision-medicine breakthrough yet.
Key takeaways
- Specific GLP-1 receptor and dopamine-pathway variants correlate with response
- Predicted differences are roughly 2–4 percentage points of body-weight loss at 12 months
- There is no clinically validated test that should change your starting protocol today
What the study found
Researchers analyzed self-reported weight outcomes against genome-wide data for tens of thousands of GLP-1 users. Several variants in the GLP-1 receptor gene and in dopamine-related pathways tracked with response, particularly with whether patients reported strong appetite suppression.
The strongest single variant added or subtracted around 1.5–2 percentage points of weight loss at 12 months — meaningful but not destiny.
Should this change your decision?
Not yet. There is no FDA-cleared genetic test that providers should be ordering before prescribing GLP-1 medications. The current data is best read as confirmation that response variability has a biological floor, not a prescribing rule.
What still works: titrating slowly, hitting protein and movement targets, and switching molecules (semaglutide vs tirzepatide) if response is poor at 12 weeks.